Table 2.

Univariate analysis of clinical variables for DMFS according to molecular subtype

	Total				HR+/HER2−				HR+/HER2+				HR−/HER2+				TNBC
	Hazard ratio	95% CI		P value	Hazard ratio	95% CI		P value	Hazard ratio	95% CI		P value	Hazard ratio	95% CI		P value	Hazard ratio	95% CI		P value
No. of patients (no. of events)		815 (209)				408 (108)				111 (32)				104 (28)				192 (41)
Age (years)
<50	1.00				1.00				1.00				1.00				1.00
≥50	0.74	0.56	0.99	0.042	0.76	0.51	1.14	0.184	0.47	0.19	1.15	0.098	0.83	0.39	1.76	0.630	0.76	0.39	1.50	0.431
Tumor size (cm)
≤2	1.00				1.00				1.00				1.00				1.00
2–5	1.70	1.25	2.30	0.001	1.59	1.06	2.40	0.025	1.13	0.53	2.43	0.745	2.39	0.90	6.35	0.081	2.18	1.02	4.63	0.044
>5	2.13	1.26	3.60	0.005	2.25	1.08	4.66	0.029	1.05	0.23	4.82	0.947	1.68	0.32	8.64	0.538	3.91	1.31	11.68	0.015
Lymph node status
Negative	1.00				1.00				1.00				1.00				1.00
Positive	2.74	2.04	3.68	<0.001	3.04	1.99	4.66	<0.001	2.78	1.20	6.42	0.017	1.87	0.88	3.96	0.101	2.82	1.51	5.29	0.001
Histologic grade
1	1.00				1.00				1.00				–				–
2	1.64	0.90	2.97	0.104	1.56	0.83	2.94	0.169	1.13	0.13	9.64	0.914	1.00				1.00
3	2.40	1.35	4.26	0.003	2.33	1.22	4.44	0.010	3.89	0.52	28.90	0.184	1.05	0.41	2.65	0.925	1.36	0.59	3.14	0.468

Hazard ratios with P values < 0.05 are marked in bold

HR hormone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, CI confidence interval